Vanessa Preumont

1.0k total citations · 1 hit paper
44 papers, 498 citations indexed

About

Vanessa Preumont is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Vanessa Preumont has authored 44 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Vanessa Preumont's work include Diabetes Management and Research (25 papers), Diabetes Treatment and Management (20 papers) and Metabolism, Diabetes, and Cancer (9 papers). Vanessa Preumont is often cited by papers focused on Diabetes Management and Research (25 papers), Diabetes Treatment and Management (20 papers) and Metabolism, Diabetes, and Cancer (9 papers). Vanessa Preumont collaborates with scholars based in Belgium, Netherlands and United States. Vanessa Preumont's co-authors include Martin Buysschaert, Michel P. Hermans, Dominique Tennstedt, Dominique Maiter, Liliane Marot, Emilie Hendrickx, Laure Dumoutier, Marie Baeck, Patrick Lebecque and Isabelle Pâris and has published in prestigious journals such as Diabetes Care, Diabetologia and British Journal of Dermatology.

In The Last Decade

Vanessa Preumont

37 papers receiving 491 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial

2024 55 citations Katrien Benhalima, Dominique Ballaux et al. The Lancet Diabetes & Endocrinology profile →

Peers

Vanessa Preumont

EDM

SURGE

GENET

IMMUN

Shan Lang China

Élise Bismuth France

Natalia Nowak Poland

Jessica Hwang United States

José María Pou Spain

Silvia Velázquez-García Spain

Evrim Çakır Türkiye

Macarena Alpañés Spain

S. Munkgaard Rasmussen Denmark

Daniele Cappellani Italy

Shan Lang China

Vanessa Preumont

233 ×0.7

EDM

236 ×1.4

SURGE

168 ×1.5

104 ×1.4

GENET

35 ×0.5

IMMUN

Citations per year, relative to Vanessa Preumont Vanessa Preumont (= 1×) peers Shan Lang

Countries citing papers authored by Vanessa Preumont

Since Specialization

Citations

This map shows the geographic impact of Vanessa Preumont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Preumont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Preumont more than expected).

Fields of papers citing papers by Vanessa Preumont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Preumont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Preumont. The network helps show where Vanessa Preumont may publish in the future.

Co-authorship network of co-authors of Vanessa Preumont

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Preumont. A scholar is included among the top collaborators of Vanessa Preumont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Preumont. Vanessa Preumont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ballaux, Dominique, Gerd Vanhaverbeke, Youri Taes, et al.. (2025). Cost-effectiveness of advanced hybrid closed loop therapy compared to standard insulin therapy for type 1 diabetes in pregnancy: an economic evaluation of the CRISTAL trial. EClinicalMedicine. 81. 103106–103106. 2 indexed citations

Peeters, Marc, Dominique Ballaux, Gerd Vanhaverbeke, et al.. (2025). Who Benefits Most from Advanced Hybrid Closed Loop Therapy in Pregnancy Across Different Subgroups: A Secondary Analysis of the Randomized Controlled CRISTAL Trial. Diabetes Technology & Therapeutics. 28(3). 253–263.

Gohy, Sophie, et al.. (2024). Novel time-saving OGTT sparing HbA1c-HOMA2 based algorithm for the diagnosis of cystic fibrosis-related diabetes. Diabetes Research and Clinical Practice. 208. 111124–111124. 1 indexed citations

Benhalima, Katrien, Dominique Ballaux, Gerd Vanhaverbeke, et al.. (2024). Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. The Lancet Diabetes & Endocrinology. 12(6). 390–403. 55 indexed citations breakdown →

Buysschaert, Martin, et al.. (2023). Advances in cystic fibrosis-related diabetes: Current status and future directions. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 17(11). 102899–102899. 14 indexed citations

Gohy, Sophie, et al.. (2023). Combined CFTR modulator therapies are linked with anabolic benefits and insulin-sparing in cystic fibrosis-related diabetes. Journal of Clinical & Translational Endocrinology. 33. 100320–100320. 11 indexed citations

Ballaux, Dominique, Gerd Vanhaverbeke, Youri Taes, et al.. (2023). Closed-loop insulin delivery in pregnant women with type 1 diabetes (CRISTAL): a multicentre randomized controlled trial – study protocol. BMC Pregnancy and Childbirth. 23(1). 180–180. 19 indexed citations

Buysschaert, Martin, et al.. (2019). Impact of flash glucose monitoring on glycaemic control and quality of life in patients with type 1 diabetes: A 18-month follow-up in real life. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 14(2). 65–69. 16 indexed citations

Maiter, Dominique, et al.. (2018). Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: A retrospective real-life study in 131 patients. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 13(1). 332–336. 19 indexed citations

10.

Buysschaert, Martin, et al.. (2016). An elevated 1-h post- load glucose level during the oral glucose tolerance test detects prediabetes. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 11(2). 137–139. 5 indexed citations

11.

Buysschaert, Martin, et al.. (2015). ROOTS: A multicenter study in Belgium to evaluate the effectiveness and safety of liraglutide (Victoza®) in type 2 diabetic patients. Diabetes & Metabolic Syndrome Clinical Research & Reviews. 9(3). 139–142. 22 indexed citations

12.

Preumont, Vanessa, Michel P. Hermans, Michael Bergman, & Martin Buysschaert. (2013). Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes.. PubMed. 67(6). 411–5. 6 indexed citations

13.

Buysschaert, Martin, Dominique Tennstedt, & Vanessa Preumont. (2012). Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes & Metabolism. 38(1). 86–88. 39 indexed citations

14.

Preumont, Vanessa, et al.. (2011). Transient Efficacy of Octreotide and Pasireotide (SOM230) Treatment in GIP-dependent Cushing's Syndrome. Hormone and Metabolic Research. 43(4). 287–291. 33 indexed citations

15.

Buysschaert, Martin, et al.. (2010). One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice. Diabetes & Metabolism. 36(5). 381–388. 56 indexed citations

16.

Preumont, Vanessa, Michel P. Hermans, S. Brichard, & Martin Buysschaert. (2010). Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes & Metabolism. 36(4). 293–298. 23 indexed citations

17.

Preumont, Vanessa, Michel P. Hermans, Martin Buysschaert, & Jacques Jamart. (2009). Special Considerations in the Management and Education of Older Persons With Diabetes. Diabetes & Metabolism. 35. 7 indexed citations

18.

Preumont, Vanessa, et al.. (2009). INSULIN DETEMIR IN ROUTINE CLINICAL PRACTICE: A 26-WEEK FOLLOW-UP IN TYPE 1 DIABETIC PATIENTS FROM THE BELGIAN PREDICTIVE COHORT. Acta Clinica Belgica. 64(1). 49–55. 10 indexed citations

19.

Pasquet, Agnès, Vanessa Preumont, Joëlle Kefer, et al.. (2008). Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents. Diabetes & Metabolism. 34(1). 62–67. 7 indexed citations

20.

Preumont, Vanessa, Orsalia Alexopoulou, Julian Donckier, et al.. (2006). METABOLIC (GLYCAEMIC, LIPIDIC) AND BLOOD PRESSURE CONTROL IN 101 TYPE 2 DIABETIC PATIENTS ON FIRST ADMISSION TO DIABETES CENTRES. Acta Clinica Belgica. 61(3). 127–133. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact